How much revenue does Beijing SL Pharmaceutical make?

Beijing SL Pharmaceutical reported 660.42 million CNY in revenue for fiscal year 2024, down 35.1% from 1.02 billion CNY in fiscal year 2023. In Q2 2025 revenue was 135.96 million CNY.

Where does Beijing SL Pharmaceutical make most of its revenue?

East China: 30% of revenue by region in fiscal year 2025, followed by Central South China (27%).

What companies are similar to Beijing SL Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ), Hainan Haiyao Co., Ltd. (000566.SZ), Youcare Pharmaceutical Group Co., Ltd. (688658.SS), Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ).

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Stock

About Beijing SL Pharmaceutical Co., Ltd.

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptotheci...

At a glance

Beijing SL Pharmaceutical reported revenue of 660.42 million CNY for fiscal year 2024, down 35.1% from fiscal year 2023, and net income of -74.07 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 135.96 million CNY, down 7.5% from a year before. East China was its largest region in fiscal year 2025, with 30% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.